Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience
IntroductionMesenchymal stromal cells (MSC) therapy has emerged as a potential treatment option for refractory FCGS. However, there is a lack of long-term data on the use of MSC therapy in cats. This study aimed to evaluate the long-term safety and efficacy of MSC therapy for FCGS and investigate po...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Veterinary Science |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fvets.2023.1171922/full |
| _version_ | 1797840159945785344 |
|---|---|
| author | Maria Soltero-Rivera Sterling Hart Andrew Blandino Natalia Vapniarsky Natalia Vapniarsky Boaz Arzi Boaz Arzi |
| author_facet | Maria Soltero-Rivera Sterling Hart Andrew Blandino Natalia Vapniarsky Natalia Vapniarsky Boaz Arzi Boaz Arzi |
| author_sort | Maria Soltero-Rivera |
| collection | DOAJ |
| description | IntroductionMesenchymal stromal cells (MSC) therapy has emerged as a potential treatment option for refractory FCGS. However, there is a lack of long-term data on the use of MSC therapy in cats. This study aimed to evaluate the long-term safety and efficacy of MSC therapy for FCGS and investigate potential factors associated with treatment outcomes.MethodsThis study was a retrospective evaluation of 38 client-owned cats with refractory FCGS who received MSC therapy. Medical records, histopathology, and the Stomatitis Activity Disease Index (SDAI) were reviewed. Correlations of the long-term follow-up success rates with SDAI and cell line type used were conducted. A client survey was also performed to assess side effect occurrence, quality-of-life following treatment, and overall treatment satisfaction.ResultsLong-term follow-up ranged from 2 to 9 years post-MSC treatment. The overall positive response rate to MSC treatment was 65.5%, with 58.6% of cats exhibiting permanent improvement or cure. Adverse effects occurring during or immediately after treatment were noted in 34.2% of cases, the majority being transient, self-resolving transfusion-like reactions. No long-term adverse events were noted. No significant correlation in outcome was detected between allogeneic and autologous MSC treatment (p = 0.871) or the severity of the SDAI at entry (p = 0.848) or exit (p = 0.166), or the delta SDAI between entry and exit (p = 0.178). The status 6 months (none to partial improvement vs. substantial improvement to resolution) post-therapy was a predictor of long-term response (value of p < 0.041). Most clients were satisfied with the treatment and outcomes, with 90.6% willing to pursue treatment again, given a similar situation.DiscussionThe results of this study support the use of both autologous and allogeneic MSC as an efficacious and safe therapeutic option for refractory FCGS. |
| first_indexed | 2024-04-09T16:10:16Z |
| format | Article |
| id | doaj.art-bbf0a54a4d8c4958b9b363c7a02ce8ac |
| institution | Directory Open Access Journal |
| issn | 2297-1769 |
| language | English |
| last_indexed | 2024-04-09T16:10:16Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Veterinary Science |
| spelling | doaj.art-bbf0a54a4d8c4958b9b363c7a02ce8ac2023-04-24T13:51:42ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692023-04-011010.3389/fvets.2023.11719221171922Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experienceMaria Soltero-Rivera0Sterling Hart1Andrew Blandino2Natalia Vapniarsky3Natalia Vapniarsky4Boaz Arzi5Boaz Arzi6Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesDepartment of Statistics, University of California, Davis, Davis, CA, United StatesDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesVeterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesVeterinary Institute for Regenerative Cures, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesIntroductionMesenchymal stromal cells (MSC) therapy has emerged as a potential treatment option for refractory FCGS. However, there is a lack of long-term data on the use of MSC therapy in cats. This study aimed to evaluate the long-term safety and efficacy of MSC therapy for FCGS and investigate potential factors associated with treatment outcomes.MethodsThis study was a retrospective evaluation of 38 client-owned cats with refractory FCGS who received MSC therapy. Medical records, histopathology, and the Stomatitis Activity Disease Index (SDAI) were reviewed. Correlations of the long-term follow-up success rates with SDAI and cell line type used were conducted. A client survey was also performed to assess side effect occurrence, quality-of-life following treatment, and overall treatment satisfaction.ResultsLong-term follow-up ranged from 2 to 9 years post-MSC treatment. The overall positive response rate to MSC treatment was 65.5%, with 58.6% of cats exhibiting permanent improvement or cure. Adverse effects occurring during or immediately after treatment were noted in 34.2% of cases, the majority being transient, self-resolving transfusion-like reactions. No long-term adverse events were noted. No significant correlation in outcome was detected between allogeneic and autologous MSC treatment (p = 0.871) or the severity of the SDAI at entry (p = 0.848) or exit (p = 0.166), or the delta SDAI between entry and exit (p = 0.178). The status 6 months (none to partial improvement vs. substantial improvement to resolution) post-therapy was a predictor of long-term response (value of p < 0.041). Most clients were satisfied with the treatment and outcomes, with 90.6% willing to pursue treatment again, given a similar situation.DiscussionThe results of this study support the use of both autologous and allogeneic MSC as an efficacious and safe therapeutic option for refractory FCGS.https://www.frontiersin.org/articles/10.3389/fvets.2023.1171922/fullgingivostomatitisstromal cellsMSCcatsdentistryregenerative medicine |
| spellingShingle | Maria Soltero-Rivera Sterling Hart Andrew Blandino Natalia Vapniarsky Natalia Vapniarsky Boaz Arzi Boaz Arzi Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience Frontiers in Veterinary Science gingivostomatitis stromal cells MSC cats dentistry regenerative medicine |
| title | Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience |
| title_full | Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience |
| title_fullStr | Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience |
| title_full_unstemmed | Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience |
| title_short | Mesenchymal stromal cell therapy for feline chronic gingivostomatitis: Long term experience |
| title_sort | mesenchymal stromal cell therapy for feline chronic gingivostomatitis long term experience |
| topic | gingivostomatitis stromal cells MSC cats dentistry regenerative medicine |
| url | https://www.frontiersin.org/articles/10.3389/fvets.2023.1171922/full |
| work_keys_str_mv | AT mariasolterorivera mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT sterlinghart mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT andrewblandino mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT nataliavapniarsky mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT nataliavapniarsky mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT boazarzi mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience AT boazarzi mesenchymalstromalcelltherapyforfelinechronicgingivostomatitislongtermexperience |